TrialHaematologica2021

Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK

Kwee L Yong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.